News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alexion Pharmaceuticals Inc. (ALXN) Turns to Goldman, Sachs & Co. for Advice on Roche (RHHBY)



7/31/2013 7:53:47 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Alexion Pharmaceuticals Inc. (ALXN), the drugmaker whose blood-disease treatment is among the world’s most expensive medicines, engaged Goldman Sachs Group Inc. as an adviser as it prepares for a possible takeover offer from Roche Holding AG (ROG), said people with knowledge of the matter. Swiss drugmaker Roche informally approached Cheshire, Connecticut-based Alexion last week about a deal, an advance that was rebuffed, said one of the people, who asked not to be named because the overture was private. Alexion wants Goldman Sachs to help negotiate if Roche offers a price high enough to interest management, or to help defend against a possible hostile bid, another person said.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at News Release
Read at Investors


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES